Talphera Investor Relations Material
Latest events
Q1 2025
Talphera
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Talphera Inc
Access all reports
Talphera Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate is DSUVIA™ (sufentanil sublingual tablet, 30 mcg) which has completed Phase 3 trials. The Company believes that DSUVIA is a potential first-in-class non-invasive treatment option that can deliver rapid relief to patients suffering from moderate to severe acute pain.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
TLPH
Country
🇺🇸 United States